Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LZ 901

Next Previous
X
Search
Drug Profile

LZ 901

Alternative Names: LZ-901; Recombinant herpes zoster vaccine - Beijing Luzhu Biotechnology

Latest Information Update: 30 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Luzhu Biotechnology
  • Class Adjuvants; Protein vaccines; Synthetic vaccines; Varicella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Herpes zoster

Most Recent Events

  • 03 Jan 2024 Beijing Luzhu Biotechnology plans a phase II trial for Herpes Zoster in the US in second quarter of 2024 (Beijing Luzhu Biotechnology, January 2024)
  • 19 Oct 2023 Beijing Luzhu Biotechnology announces intention to submit BLA to NMPA for Herpes zoster in fourth quarter of 2024 (Beijing Luzhu Biotechnology pipeline, July 2023)
  • 28 Sep 2023 Phase-III clinical trials in Herpes zoster (Prevention) in China (IM) (NCT06088745)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top